waypoint wealth counsel Acquires New Holdings in BioMarin Pharmaceutical Inc. $BMRN

waypoint wealth counsel acquired a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 4,355 shares of the biotechnology company’s stock, valued at approximately $239,000.

Several other large investors have also recently modified their holdings of the business. Aberdeen Group plc raised its stake in shares of BioMarin Pharmaceutical by 30.2% during the second quarter. Aberdeen Group plc now owns 983,048 shares of the biotechnology company’s stock valued at $54,038,000 after acquiring an additional 227,773 shares during the last quarter. IFP Advisors Inc raised its stake in shares of BioMarin Pharmaceutical by 1,382.2% during the second quarter. IFP Advisors Inc now owns 1,749 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 1,631 shares during the last quarter. Callan Family Office LLC raised its stake in shares of BioMarin Pharmaceutical by 239.0% during the second quarter. Callan Family Office LLC now owns 67,038 shares of the biotechnology company’s stock valued at $3,685,000 after acquiring an additional 47,264 shares during the last quarter. Blair William & Co. IL raised its stake in shares of BioMarin Pharmaceutical by 9.0% during the second quarter. Blair William & Co. IL now owns 5,232 shares of the biotechnology company’s stock valued at $288,000 after acquiring an additional 432 shares during the last quarter. Finally, Vontobel Holding Ltd. raised its stake in shares of BioMarin Pharmaceutical by 68.1% during the second quarter. Vontobel Holding Ltd. now owns 7,901 shares of the biotechnology company’s stock valued at $434,000 after acquiring an additional 3,202 shares during the last quarter. Institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Trading Down 2.8%

BMRN opened at $52.32 on Monday. BioMarin Pharmaceutical Inc. has a twelve month low of $51.78 and a twelve month high of $73.51. The company has a quick ratio of 3.60, a current ratio of 5.56 and a debt-to-equity ratio of 0.10. The company has a fifty day moving average of $56.37 and a 200-day moving average of $57.99. The stock has a market cap of $10.05 billion, a PE ratio of 15.53, a price-to-earnings-growth ratio of 0.70 and a beta of 0.33.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. HC Wainwright assumed coverage on shares of BioMarin Pharmaceutical in a research note on Monday, September 8th. They set a “neutral” rating and a $60.00 price target for the company. Wolfe Research set a $95.00 price target on shares of BioMarin Pharmaceutical and gave the company an “outperform” rating in a research note on Tuesday, July 15th. Raymond James Financial began coverage on shares of BioMarin Pharmaceutical in a research note on Wednesday, September 3rd. They set an “outperform” rating and a $85.00 price target for the company. JPMorgan Chase & Co. increased their price objective on shares of BioMarin Pharmaceutical from $116.00 to $119.00 and gave the stock an “overweight” rating in a research report on Thursday. Finally, Guggenheim increased their price objective on shares of BioMarin Pharmaceutical from $101.00 to $106.00 and gave the stock a “buy” rating in a research report on Wednesday, August 6th. Thirteen investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $93.26.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.